Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cyberonics (cybx) epilepsy therapy recommonded -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (456)	4/24/2006 2:06:10 AM
From: mopgcw	Respond to of 471

covered too early... UPDATE 2-Cyberonics off as Aetna denies coverage for device Fri Apr 21, 2006 4:52 PM ET (Adds Aetna comment, closing stock price) CHICAGO, April 21 (Reuters) - Shares of Cyberonics Inc. (CYBX.O: Quote, Profile, Research) fell as much as 8 percent on Friday after health insurer Aetna Inc. (AET.N: Quote, Profile, Research) said it would not provide coverage for the company's implantable device to treat severe depression. FACT BOX CYBX.O (Cyberonics Inc) Last: $24.93 Change: -1.80 Up/Down: -6.73% In a bulletin posted on its Web site, Aetna, one of the largest U.S. insurers, said it will approve payment for the device when used to treat epilepsy, but for no other indication, including refractory depression, autism and obesity. The insurer said it considers the device, the Vagus Nerve Stimulation Therapy System, which delivers intermittent electrical pulses to the brain, "experimental and investigational." It said the stop-watch-sized device's effectiveness has not been established through well-controlled clinical trials. Aetna, as well as other insurers, had been reviewing claims for reimbursement on a case-by-case basis. An Aetna spokeswoman said the company will continue to review claims case by case. Analysts said the decision could set a precedent for other insurers. "This morning's decision by one of the nation's largest insurers to deny coverage of the device for depression will likely, we believe, stifle what limited demand the device already had and discourage other insurers from offering coverage," said Alexander Arrow, an analyst at Lazard Capital Markets, who recommended investors sell the stock. The U.S. Food and Drug Administration approved the device last July for adults with depression who had failed to respond to other therapies. Aetna, however, said that "long-term data regarding tolerability as well as symptomatic and functional outcomes of depressed patients receiving VNS are needed to ascertain the effectiveness of this procedure for treating refractory depression." Cyberonics Chief Financial Officer Pamela Westbrook said Aetna's decision would not change the company's most recent financial outlook. "This is business as usual. We have not anticipated broad, national coverage for the next four quarters and it wasn't contemplated in our guidance," Westbrook said. Earlier this year Sen. Charles Grassley, chairman of the Senate Finance Committee and a critic of the FDA, said he was concerned that the device might not meet the usual FDA criteria for safety and efficacy. Shares of Cyberonics closed $1.80, or 6.7 percent, lower at $24.93 on Nasdaq after falling as low as $24.60 earlier.

To: keokalani'nui who wrote (456)	8/9/2006 7:24:54 AM
From: mopgcw	Respond to of 471

the hits keep coming... Blue Cross rejection sends Cyberonics stock tumbling Tuesday August 8, 5:08 pm ET Cyberonics Inc.'s stock slid by 4 percent on Tuesday after the Blue Cross Blue Shield Association rejected an appeal by the company to pay for its depression device. Information presented by Cyberonics contained "nothing new," according to a Reuters report citing Naomi Aronson, executive director of the technology evaluation center at Blue Cross Blue Shield, the trade association for 38 independently owned Blue Cross health insurance plans. Calls to Aronson by the Houston Business Journal were not immediately returned. Many of the major insurance carriers have resisted providing reimbursement for Cyberonics' Vagus Nerve Stimulator as a treatment for depression. In April, Aetna Inc. declined coverage of the device. Such rejections come as a big blow to the company, which has been struggling since last summer to convince insurers to cover the device for patients. Cyberonics' implantable, pacemaker-like device was approved in 1997 to deliver vagus nerve stimulation, or VNS, therapy to epilepsy patients. Last summer, Cyberonics received long-awaited approval from the U.S. Food and Drug Administration to market the apparatus to treat depression. Aronson said the association will post its decision on its Web site within the next few weeks, according to Reuters. On Aug. 1, Cyberonics' (NASDAQ:CYBX - News) shares plummeted to a new 52-week low of $14.70 after the company announced that it had received a Nasdaq letter addressing possible delisting from the stock exchange for non-compliance. The activity came despite the company's projection for higher first-quarter sales. Cyberonics' stock closed down 4 percent Tuesday afternoon to $15.80, far from a 52-week-high of $40.69. Published August 8, 2006 by the Houston Business Journal